| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Process | STA Standard |
| ID number | 6377 |
Provisional Schedule
| Draft guidance | 06 December 2024 - 10 January 2025 |
| Committee meeting: 2 | 12 February 2025 |
| Expected publication | 16 April 2025 |
Project Team
| Project lead | Greg O'Toole |
Email enquiries
- If you have any queries please email TATeam7@nice.org.uk
| External Assessment Group | Kleijnen Systematic Reviews Ltd |
Stakeholders
| Companies sponsors | Novartis Pharmaceuticals (ruxolitinib) |
| Others | Department of Health and Social Care |
| NHS England | |
| Patient carer groups | Anthony Nolan |
| Leukaemia Care | |
| Professional groups | British Society of Blood and Marrow Transplantation and Cellular Therapy |
| Royal College of Physicians | |
| Associated public health groups | None |
| Comparator companies | Pfizer (sirolimus) (confidentiality agreement not signed, not participating) |
| Roche Products (mycophenolate mofetil) (confidentiality agreement not signed, not participating) | |
| Rosemont Pharmaceuticals (mycophenolate mofetil) (confidentiality agreement not signed, not participating) | |
| Teva Pharma (mycophenolate mofetil) (confidentiality agreement not signed, not participating) | |
| Therakos UK (confidentiality agreement signed, participating) | |
| Tillomed Laboratories (mycophenolate mofetil) (confidentiality agreement not signed, not participating) | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health - Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| Scottish Medicines Consortium | |
| Welsh Government | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | None |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 06 November 2024 | Committee meeting |
| 06 November 2024 | Declaration of interests |
| 15 April 2024 | Invitation to participate |
| 07 March 2024 - 20 March 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6377 |
| 07 March 2024 | In progress. Scoping commenced. |
| 01 February 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 01 February 2024 | The appraisal is expected to start during March 2024 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an invitation to participate in the appraisal during mid-April 2024. |
For further information on our processes and methods, please see our CHTE processes and methods manual